Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexchlorpheniramine
Drug ID BADD_D00626
Description Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.
Indications and Usage Not Available
Marketing Status experimental; investigational
ATC Code R06AB02
DrugBank ID DB13679
KEGG ID D07803
MeSH ID C018904
PubChem ID 33036
TTD Drug ID D05ZGQ
NDC Product Code Not Available
UNII 3Q9Q0B929N
Synonyms dexchlorpheniramine | dexclorfeniramine | dexchlorpheniramine, (+-)-isomer | dexchlorpheniramine, (R)-isomer | dexchlorpheniramine, monohydrochloride, (S)-isomer | Dexclor | Polaramine | Polaramin | dexchlorpheniramine monohydrochloride | Polaronil | dexchlorpheniramine maleate | dextrochlorpheniramine maleate | dexchlorpheniramine maleate (1:1), (+-)-isomer | dexchlorpheniramine maleate (1:1), (R)-isomer | dexchlorpheniramine maleate (1:1), (S)-isomer | dexchlorpheniramine sodium maleate (1:1) | Polargen TD
Chemical Information
Molecular Formula C16H19ClN2
CAS Registry Number 25523-97-1
SMILES CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001---
Asthenia08.01.01.001---
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.002---
Chills08.01.09.001; 15.05.03.016--
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Conversion disorder19.24.01.001---
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.001---
Dyspepsia07.01.02.001--
Euphoric mood19.04.02.006--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Haemolytic anaemia01.06.03.002---
Hyperhidrosis08.01.03.028; 23.02.03.004--
Insomnia17.15.03.002; 19.02.01.002--
Irritability08.01.03.011; 19.04.02.013--
Labyrinthitis04.04.03.001; 11.01.05.002---
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervousness19.06.02.003---
Neuritis17.09.03.001---
Neuropathy peripheral17.09.03.003---
Paraesthesia17.02.06.005; 23.03.03.094--
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Seizure17.12.03.001--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene